Listen to Medscape InDiscussion: Myelofibrosis, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Medscape InDiscussion: Myelofibrosis
Claim This Podcastby Medscape
5.0(1 reviews)
12 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
40
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality43
Social0
YouTube93
Engagement0
Podcast Overview
Listen to Medscape InDiscussion: Myelofibrosis, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Language
🇺🇲
Publishing Since
7/3/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
40
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality43
Social0
YouTube93
Engagement0
7
Excellent Areas
2
Good Performance
10
Growth Opportunities
excellent
Episode Length
25 minutes
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 31 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Medscape InDiscussion: Myelofibrosis
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 10, 2025
S2 Episode 6: A Futuristic Vision for Treating Myelofibrosis
<p>What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002058. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Manipulating Hepcidin in Polycythemia Vera https://pubmed.ncbi.nlm.nih.gov/37383006/</p> <p>Role of ASXL1 and TP53 Mutations in the Molecular Classification and Prognosis of Acute Myeloid Leukemias With Myelodysplasia-Related Changes https://pubmed.ncbi.nlm.nih.gov/25860933/</p> <p>Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion Into KMT2A in a Patient With Acute Monoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/40149468/ </p> <p>8p11 Myeloproliferative Syndrome: A Review https://pubmed.ncbi.nlm.nih.gov/20226962/</p> <p>What's Next? Clinical Trials in Myelofibrosis https://www.medscape.com/viewarticle/1002053</p> <p>Artificial Intelligence-Based Morphological Fingerprinting of Megakaryocytes: A New Tool for Assessing Disease in MPN Patients https://pubmed.ncbi.nlm.nih.gov/32706893/</p> <p>Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies https://pubmed.ncbi.nlm.nih.gov/37290996/</p> <p>The Telomerase Inhibitor Imetelstat Differentially Targets JAK2V617F Versus CALR Mutant Myeloproliferative Neoplasm Cells and Inhibits JAK-STAT Signaling https://pubmed.ncbi.nlm.nih.gov/37941547/</p> <p>A Novel Application of XPO1 Inhibition for the Treatment of Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/40454401/</p> <p>BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/36416118/</p> <p>Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/</p> <p>Center for International Blood & Marrow Transplant Research (CIBMTR) https://cibmtr.org/</p> <p>Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/ </p> <p>Clearance of Driver Mutations After Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/39778169/ </p> <p>Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment https://ashpublications.org/blood/article/144/Supplement%201/871/531067/Development-of-a-First-in-Class-CAR-T-Therapy</p>
June 10, 2025
S2 Episode 5: Posttransplant Monitoring in Myelofibrosis
Drs. Tania Jain and Rachel Salit discuss post-transplant monitoring in myelofibrosis, covering remission definitions, relapse monitoring, and patient-centered transplant decisions in this interview episode.
May 8, 2025
S2 Episode 4: JAK Inhibitors: Too Many Choices or Not Enough?
<p>Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat myelofibrosis.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002056. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview</p> <p>JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/32903304/</p> <p>You Really Got a Hold on Me https://ashpublications.org/ashclinicalnews/news/6493/You-Really-Got-a-Hold-on-Me</p> <p>A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/22375971/</p> <p>Overall Survival in the SIMPLIFY-1 and SIMPLIFY-2 Phase 3 Trials of Momelotinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35869266/</p> <p>Biological Basis for Efficacy of Activin Receptor Ligand Traps in Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/31961337/</p> <p>Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (ODYSSEY) https://clinicaltrials.gov/study/NCT06517875</p> <p>Biology and Therapeutic Targeting of Molecular Mechanisms in MPNs https://pubmed.ncbi.nlm.nih.gov/36534936/</p> <p>Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) https://clinicaltrials.gov/study/NCT03627403</p> <p>Selinexor Plus Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis: SENTRY Phase 3 Study Design https://pubmed.ncbi.nlm.nih.gov/39911057/</p> <p>EHA 2023, Abstract 210: An Open-Label, Global, Phase (Ph) 1b/2 Study Adding Navtemadlin (Nvtm) to Ruxolitinib (Rux) in Patients (Pts) With Primary or Secondary Myelofibrosis (Mf) Who Have a Suboptimal Response to Rux https://library.ehaweb.org/eha/2023/eha2023-congress/387910/john.mascarenhas.an.open-label.global.phase.28ph29.1b.2.study.adding.navtemadlin.html</p> <p>Imetelstat in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK Inhibitor: IMpactMF Phase III Study Design https://pubmed.ncbi.nlm.nih.gov/35510486/</p> <p>CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/26175413/</p> <p>Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose With Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV) https://ashpublications.org/blood/article/144/Supplement%201/4568/533799/Ropeginterferon-Alfa-2b-ROPEG-and-Peginterferon</p> <p>The Characteristics of CALR Mutations in Myeloproliferative Neoplasms: A Clinical Experience From a Tertiary Care Center in Qatar and a Literature Review https://pubmed.ncbi.nlm.nih.gov/38804886/</p> <p>Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40065169/</p> <p>TRANSFORM-1 Trial of Navitoclax in Combination With Ruxolitinib for Myelofibrosis Met Primary but Not Secondary Endpoint https://ashpublications.org/ashclinicalnews/news/7630/TRANSFORM-1-Trial-of-Navitoclax-in-Combination</p> <p>Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/34138638/</p> <p>Efficacy and Safety of Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (FREEDOM2): Results From a Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/39265613/</p> <p>Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib: An Updated Analysis of the JAKARTA2 Study Using Stringent Criteria for Ruxolitinib Failure https://pubmed.ncbi.nlm.nih.gov/32129512/</p> <p>Impact of TP53 on Outcome of Patients With Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation https://pubmed.ncbi.nlm.nih.gov/36940410/</p> <p>SURPASS-ET: Phase III Study of Ropeginterferon Alfa-2b Versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia https://pubmed.ncbi.nlm.nih.gov/35924546/</p> <p>EXCEED-ET: A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS7088</p> <p>Ropeginterferon alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study https://pubmed.ncbi.nlm.nih.gov/32014125/</p> <p>Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/</p>
12 total episodes available
Recent guests on Medscape InDiscussion: Myelofibrosis
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Tania Jain
Guest
Rachel Salit
Guest
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Medscape InDiscussion: Myelofibrosis
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Medscape InDiscussion: Myelofibrosis?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.